Biogen (BIIB) PT Raised to $274 at Wedbush, Following CFO Transition, Earnings
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $212.55 +1.63%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 16 | New: 37
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 16 | New: 37
Join SI Premium – FREE
Wedbush analyst Laura Chico raised the price target on Biogen (NASDAQ: BIIB) to $274.00 (from $262.00) while maintaining a Neutral rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wolfe Research Upgrades Biogen (BIIB) to Outperform
- DeFi Technologies (DEFT) PT Lowered to $1 at Benchmark Following Q2 Miss
- Clean Energy Fuels (CLNE) PT Lowered to $2.50 at Raymond James
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
